---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-035521"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2025-11-18T23:59:59+00:00"
generated_at: "2026-05-16T18:51:26.113778+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tivic Health secures BARDA Techwatch meeting for Entolimod ARS program

## Summary
- Meeting with BARDA's Radiological and Nuclear Medical Countermeasures Program staff to discuss Entolimod for acute radiation syndrome.
- Tivic will present clinical data, manufacturing readiness, and BLA preparations; meeting may lead to funding or purchasing.
- Entolimod has FDA Fast Track and Orphan Drug designations for ARS.
- CEO states this supports strategy for government partnership or acquisition pathway.

## SEC filing metadata
- accession: 0001437749-25-035521
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2025-11-18T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000143774925035521/0001437749-25-035521-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000143774925035521/tivc20251117_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-035521
- JSON: https://secwatch.observer/filing/0001437749-25-035521.json
- Plain text: https://secwatch.observer/filing/0001437749-25-035521.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.